B.1.1.7 SARS-CoV-2 Variant More Transmissible but Not Linked to More Severe Illness, Death
Second study shows no change in symptoms, disease duration, reinfection rates with B.1.1.7, but reveals multiplicative increase in R1
COVID19
Moderna COVID-19 Vaccine 90% Effective 6 Months After Second Dose
Company also says vaccine is 95 percent effective against severe cases of the disease
Graded Administration of Second COVID-19 Vaccine Dose After Hypersensitivity
Current recommendations surrounding the administration of the second COVID-19 vaccine dose to patients who experience an immediate hypersensitivity reaction to the first dose are conflicting.
Rare Thrombosis, Thrombocytopenia Seen After AstraZeneca COVID-19 Vaccine
Reports document 16 reactions in young European patients following first dose of ChAdOx1 nCoV-19 vaccine
CDC, FDA Recommend Pausing Use of Janssen COVID-19 Vaccine After Reports of Rare Blood Clot
In all 6 cases, symptoms developed 6 to 13 days after vaccination.
Lucira Check It Test Kit Available OTC for At-Home COVID-19 Testing
The Lucira Check It COVID-19 test kit utilizes a molecular amplification technology to detect SARS-CoV-2 RNA.
FDA to Decide ‘Quickly’ on Pfizer Request to Approve COVID-19 Vaccine for Children 12 to 15
Currently, the FDA allows the Pfizer vaccine to be given to people 16 years and older
Trial Evaluating Dapagliflozin in Hospitalized COVID-19 Patients Misses Endpoints
The DARE-19 trial evaluated dapagliflozin in addition to standard of care in reducing disease progression, clinical complications and all-cause mortality in 1250 adults hospitalized with COVID-19.
CDC: Risk for Catching Coronavirus From Surfaces Is Low
Agency says the risk for contracting the virus from a contaminated surface is less than 1 in 10,000
In-Hospital SARS-CoV-2 Mortality Declined Throughout Pandemic
Authors say reductions in in-hospital mortality likely due to new therapies and improvements in clinical management of patients with SARS-CoV-2
